M2Gen gets private equity investment
March 18, 2021 - M2Gen, a Tampa company that runs one the world's largest observational research studies in cancer, has new majority ownership. Clayton Dubilier & Rice funds, the Merck Global Health Innovation Fund and McKesson Ventures invested an undisclosed amount to recapitalize M2Gen, a news release said. Existing shareholders Moffitt Cancer Center, Hearst Healthcare and The Ohio State University Foundation continue to hold a significant minority interest M2Gen, according to the release. In conjunction with the recapitalization, Sandra Peterson, operating partner at Clayton Dubilier & Rice, was named chair of the M2Gen board. M2Gen separately announced a new five-year agreement with Merck. Under the terms of the agreement, M2Gen will provide patient-consented, de-identified, linked clinical and genomic data in support of Merck’s oncology efforts.